日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2

SAKK 19/17：对PD-L1阳性、晚期非小细胞肺癌且体能状态评分为2的患者进行一线度伐利尤单抗治疗的安全性分析

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-020-02757-8
Mark, Michael; Froesch, Patrizia; Eboulet, Eric Innocents; Addeo, Alfredo; Pless, Miklos; Rothschild, Sacha I; Janthur, Wolf-Dieter; Burmeister, Henning; Friedlaender, Alex; Schneider, Martina; Metaxas, Yannis; Joerger, Markus; Wannesson, Luciano; Schwitter, Michael; Baudoux, Nathalie; Weindler, Susanne; Biaggi-Rudolf, Christine; Früh, Martin
肺癌
肿瘤
肿瘤免疫
PD-L1
细胞生物学
发表日期：2021
文献求助 收藏

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort

来那度胺对急性髓系白血病骨髓微环境的影响：HOVON103 AML/SAKK30/10 瑞士试验队列的转化分析

期刊:Annals of Hematology
影响因子:3
doi:10.1007/s00277-021-04467-2
Magdalena M Brune, Georg Stüssi, Pontus Lundberg, Visar Vela, Dominik Heim, Markus G Manz, Eugenia Haralambieva, Thomas Pabst, Yara Banz, Mario Bargetzi, Rainer Grobholz, Martin Fehr, Sergio Cogliatti, Gert J Ossenkoppele, Bob Löwenberg, Christina Biaggi Rudolf, Qiyu Li, Jakob Passweg, Luca Mazzuche
信号转导
肿瘤
白血病
Translational Control
发表日期：2021
文献求助 收藏

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

滤泡性淋巴瘤患者长期利妥昔单抗维持治疗：SAKK 35/03随机试验的长期结果

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2020002858
Moccia, Alden A; Taverna, Christian; Schär, Sämi; Vanazzi, Anna; Rondeau, Stéphanie; Hitz, Felicitas; Mingrone, Walter; Pabst, Thomas; Cevreska, Lidija; Del Giglio, Auro; Raats, Johann; Rauch, Daniel; Vorobiof, Daniel A; Lohri, Andreas; Ruegsegger, Céline; Biaggi Rudolf, Christine; Rusterholz, Corinne; Hayoz, Stefanie; Ghielmini, Michele; Zucca, Emanuele
淋巴瘤
发表日期：2020
文献求助 收藏

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

滤泡性淋巴瘤单药利妥昔单抗诱导治疗后，利妥昔单抗维持治疗最长可达5年：随机对照III期试验SAKK 35/03的结果

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2015.61.3968
Taverna, Christian; Martinelli, Giovanni; Hitz, Felicitas; Mingrone, Walter; Pabst, Thomas; Cevreska, Lidija; Del Giglio, Auro; Vanazzi, Anna; Laszlo, Daniele; Raats, Johann; Rauch, Daniel; Vorobiof, Daniel A; Lohri, Andreas; Biaggi Rudolf, Christine; Rondeau, Stéphanie; Rusterholz, Corinne; Heijnen, Ingmar A F M; Zucca, Emanuele; Ghielmini, Michele
淋巴瘤
发表日期：2016
文献求助 收藏